CCT2 and cholangiocarcinoma: CCT2 expression was significantly higher in BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), CHOL (Cholangiocarcinoma), COAD (colon adenocarcinoma), ESCA (Esophageal carcinoma), HNSC (head and neck cancer), KIRP (Kidney renal papillary cell carcinoma), LIHC (liver hepatocellular carcinoma), LUAD (lung adenocarcinoma), LUSC (Lung squamous cell carcinoma), PRAD (Prostate adenocarcinoma), READ (Rectum adenocarcinoma), STAD (stomach adenocarcinoma), and UCEC (Uterine Corpus Endometrial Carcinoma) when compared with adjacent normal tissues.